The Latest Trading Price of Kopran Ltd is ₹ 162.1 as of 05 May 15:30
. The P/E Ratio of Kopran Ltd changed from 7.4 on March 2021 to 21.9 on March 2025 . This represents a CAGR of 24.23% over 5 yearsThe P/E Ratio of NGL Fine Chem Ltd changed from 16.7 on March 2021 to 32.6 on March 2025 . This represents a CAGR of 14.31% over 5 years The Market Cap of Kopran Ltd changed from ₹ 453.94 crore on March 2021 to ₹ 845.48 crore on March 2025 . This represents a CAGR of 13.25% over 5 yearsThe Market Cap of NGL Fine Chem Ltd changed from ₹ 947.42 crore on March 2021 to ₹ 688.7 crore on March 2025 . This represents a CAGR of -6.18% over 5 years The revenue of Kopran Ltd for the Dec '25 is ₹ 194.35 crore as compare to the Sep '25 revenue of ₹ 117.93 crore. This represent the growth of 64.8% The revenue of NGL Fine Chem Ltd for the Dec '25 is ₹ 132.12 crore as compare to the Sep '25 revenue of ₹ 122.31 crore. This represent the growth of 8.02% The ebitda of Kopran Ltd for the Dec '25 is ₹ 17.83 crore as compare to the Sep '25 ebitda of ₹ -5.25 crore. This represent the decline of -439% The ebitda of NGL Fine Chem Ltd for the Dec '25 is ₹ 26.93 crore as compare to the Sep '25 ebitda of ₹ 19.21 crore. This represent the growth of 40.19% The net profit of Kopran Ltd changed from ₹ 11.1 crore to ₹ 9.34 crore over 7 quarters. This represents a CAGR of -9.39%
The net profit of NGL Fine Chem Ltd changed from ₹ 9.22 crore to ₹ 15.69 crore over 7 quarters. This represents a CAGR of 35.50%
The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 53.94 % on March 2025 . This represents a CAGR of -0.49% over 5 yearsThe Dividend Payout of NGL Fine Chem Ltd changed from 1.95 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of 25.08% over 5 years .
About Kopran Ltd
Kopran Limited, incorporated on April 26, 1958, was promoted by the Somani group and is a group company of Parijat Enterprises.
Company operates in two distinct business verticals.
While pharmaceutical formulations production is managed by Kopran Limited, manufacturing of API is operated under Kopran Research Laboratories Limited (KRLL).
Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs.
Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements.
About NGL Fine Chem Ltd
NGL Fine-Chem Limited was incorporated on December 18, 1981 as a Private Limited Company in the State of Maharashtra.
The Company became a Public Limited Company.
The Company has got its registered office and factory at New Bombay.
It was promoted by Mr. A.G.Lawande, Mr.R. J. Nachane joined Mr.A.G.Lawande for actively participating in the Management of the Company in 1989.
The Company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health.
FAQs for the comparison of Kopran Ltd and NGL Fine Chem Ltd
Which company has a larger market capitalization, Kopran Ltd or NGL Fine Chem Ltd?
Market cap of Kopran Ltd is 782 Cr while Market cap of NGL Fine Chem Ltd is 1,500 Cr
What are the key factors driving the stock performance of Kopran Ltd and NGL Fine Chem Ltd?
The stock performance of Kopran Ltd and NGL Fine Chem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Kopran Ltd and NGL Fine Chem Ltd?
As of May 5, 2026, the Kopran Ltd stock price is INR ₹162.1. On the other hand, NGL Fine Chem Ltd stock price is INR ₹2428.35.
How do dividend payouts of Kopran Ltd and NGL Fine Chem Ltd compare?
To compare the dividend payouts of Kopran Ltd and NGL Fine Chem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.